nafamostat has been researched along with Arteriosclerosis Obliterans in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Arteriosclerosis Obliterans: Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Urabe, Y | 1 |
| Ideishi, M | 1 |
| Sasaguri, M | 1 |
| Ikeda, M | 1 |
| Arakawa, K | 1 |
1 trial available for nafamostat and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
Beneficial effects of a serine protease inhibitor in peripheral vascular disease.
Topics: Aged; Arteriosclerosis Obliterans; Benzamidines; Chronic Disease; Exercise Test; Female; Femoral Vei | 1993 |